Table 2.
ACVR1 R206H and H3.1K27M significantly increase tumor incidence
| Virus combination | Tumor incidence (total tumors/total injected) |
|---|---|
| ACVR1 R206H; H3.1K27M | 28/31 = 90% |
| ACVR1 R206H; H3.3K27M | 20/22 = 91% |
| ACVR1 WT; H3.1K27M | 10/17 = 59% |
| ACVR1 R206H; H3.1 WT | 11/25 = 44% |
| ACVR1 WT; H3.1 WT | 15/26 = 58% |
| ACVR1 R206H | 21/26 = 81% |
| RCAS Y | 16/24 = 67% |
| ACVR1 WT | 10/20 = 50% |
| BMP4 | 13/22 = 59% |
| H3.1K27M | 14/19 = 74% |
| p value | |
| ACVR1 R206H; H3.1K27M vs ACVR1 WT; H3.1K27M | 0.0220* |
| ACVR1 R206H; H3.1K27M vs ACVR1 R206H; H3.1 WT | 0.0003*** |
| ACVR1 R206H; H3.1K27M vs ACVR1 WT; H3.1 WT | 0.0059** |
| ACVR1 R206H; H3.1K27M vs ACVR1 WT | 0.0023** |
| ACVR1 R206H; H3.1K27M vs RCAS Y | 0.0428* |
| ACVR1 R206H; H3.1K27M vs BMP4 | 0.0171* |
| ACVR1 R206H; H3.3K27M vs ACVR1 WT; H3.1K27M | 0.0262* |
| ACVR1 R206H; H3.3K27M vs ACVR1 R206H; H3.1 WT | 0.0008*** |
| ACVR1 R206H; H3.3K27M vs ACVR1 WT; H3.1 WT | 0.0204* |
| ACVR1 R206H; H3.3K27M vs ACVR1 WT | 0.0055** |
| ACVR1 R206H; H3.3K27M vs BMP4 | 0.0339* |
| ACVR1 R206H; H3.1 WT vs ACVR1 R206H | 0.0095** |
*p < 0.05; **p < 0.01; ***p < 0.001, Fisher's exact test